- A protein called Krüppel-like factor 4 (KLF4) in blood vessel cells helps prevent acute kidney injury in mice.
- Treating mice with statins protects against acute kidney injury, and KLF4 is necessary for this protection.
Washington, DC (October 15, 2015) -- Researchers have discovered that statins can help prevent kidney injury, and they've uncovered how the drugs exert their protective effect. The findings are published in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
Acute kidney injury (AKI) is an abrupt decline in kidney function that often arises after major surgeries or severe infections. Previous research has shown that endothelial cells that line blood vessels in the kidneys play an important role in the development of AKI. In addition, studies by Tadashi Yoshida, MD, PhD (Keio University, in Tokyo, Japan) and his colleagues indicate that a protein called Krüppel-like factor 4 (KLF4)--which controls the expression of cell adhesion molecules that recruit and activate circulating inflammatory cells--in endothelial cells helps to regulate blood vessel thickness when arteries are injured. Because of these findings, the team recently looked at the role of KLF4 in AKI.
Through experiments conducted in mice, the investigators found that KLF4 in endothelial cells helps prevent AKI, in part by suppressing inflammation. Indeed, loss of endothelial KLF4 exacerbated AKI in the animals. Moreover, the team showed that treating mice with statins can protect against AKI and that KLF4 is necessary for this protection.
"These results are highly novel and of major significance, in that they provide evidence that endothelial KLF4 is a mediator of statins as well as a novel therapeutic target for AKI," said Dr. Yoshida.
Disclosures: The authors report no financial disclosures.
Study co-authors include Matsuhiko Hayashi, MD, PhD, Maho Yamashita, MS, and Mieko Iwai, MS.
The article, entitled "Endothelial Krüppel-Like Factor 4 Mediates the Protective Effect of Statins against Ischemic AKI," will appear online at http://jasn.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with nearly 16,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.